Fuda Cancer Hospital
| China | Turkey | Austria | |
| Stomach cancer surgery | from $18,500 | from $8,500 | from $30,000 |
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Gastric intestinal metaplasia is not stomach cancer. It is a precancerous change where stomach lining cells transform to resemble intestinal cells. While this increases cancer risk, only 0.25% to 2.5% of cases progress to malignancy over many years. Regular gastroscopy surveillance remains essential.
Bookimed Expert Insight: Patients seeking diagnosis in China benefit from high-volume centers like Fuda Cancer Hospital, which has treated over 30,000 international patients. Clinical expertise here is significant, with specialists like Prof. Liu Shi Xin at Xiamen Humanity Hospital holding elite national honors. This high patient volume often leads to more precise gastroscopy interpretations, which is vital for distinguishing between simple metaplasia and higher-risk dysplasia.
Patient Consensus: Many patients feel initially panicked by the term precancerous, but note it is a microscopic change rather than a tumor. They emphasize that clearing a Helicobacter pylori infection is the most proactive step to take after a diagnosis.
Gastric intestinal metaplasia can completely reverse in some cases. Long-term clinical data shows regression is possible if caught early. Success depends on eliminating chronic irritants like Helicobacter pylori infections. Complete reversal is a multi-year biological process. This typically requires three to ten years of management.
Bookimed Expert Insight: Patient data indicates that high-volume centers like Fuda Cancer Hospital in Guangzhou prioritize advanced diagnostics for gastric issues. Their expertise in oncological monitoring suggests that accurate pathology review is the most critical factor for patients in China. These JCI-accredited facilities often focus on precise staging to differentiate between simple metaplasia and high-risk dysplasia.
Patient Consensus: Patients often emphasize that while symptoms like reflux may disappear after treatment, the microscopic metaplasia frequently remains on follow-up biopsies. They stress that testing for Helicobacter pylori is the most vital first step to prevent further progression.
The first step in treating gastric metaplasia is the detection and eradication of Helicobacter pylori infection. Eliminating this bacteria reduces chronic inflammation. This helps stop the progression toward tissue changes. It gives the stomach lining a vital chance to heal properly.
Bookimed Expert Insight: While general guidelines focus on eradication, China's oncology-centric facilities like Fuda Cancer Hospital emphasize specialized diagnostic mapping. Since metaplasia can be patchy, these centers often use precise gastroscopy to monitor tissue. Fuda alone has served over 30,000 international patients, showing the high-volume expertise available in the region.
Patient Consensus: Patients note that some cases show no symptoms despite biopsy results. They emphasize asking for specific pathology wording and tracking the exact locations where biopsies were taken.
In China, gastroscopy frequency for gastric metaplasia depends on your specific biopsy risk level. Low-risk patients generally require screening every 3 to 5 years. High-grade precancerous lesions or extensive involvement require intensive monitoring every 3 to 6 months to ensure safety.
Bookimed Expert Insight: Patient volume impacts diagnostic precision in China. Fuda Cancer Hospital serves over 30,000 international patients and is JCI-accredited. This high case volume means specialists like Dr. Song Shijun often see complex metaplasia cases daily. This experience helps in identifying subtle tissue changes that lower-volume centers might miss during routine checks.
Patient Consensus: Patients emphasize that biopsy findings matter more than the term metaplasia alone. Many note that treating H. pylori first often simplifies the long-term monitoring schedule significantly.
Chinese hospitals use high-definition video endoscopes integrated with real-time artificial intelligence and magnetically controlled capsule technology. These systems allow for precise screening of gastric metaplasia and early-state lesions. Advanced optical imaging and robotic guidance enable high-resolution visualization without invasive tubes in many specialized oncology centers.
Bookimed Expert Insight: Patient data suggests looking beyond the scope technology itself when treating gastric metaplasia. In centers like Fuda Cancer Hospital, which treats 30,000+ international patients, the value lies in combining gastroscopy with specialized minimally invasive follow-ups. While headline technology like robot-guided capsules is available, the most effective outcomes for metaplasia come from high-volume centers that prioritize aggressive biopsy protocols over imaging alone.
Patient Consensus: Patients note that sedation availability and the thoroughness of the biopsy protocol are more critical than the specific equipment brand. Many emphasize bringing prior pathology reports to ensure the endoscopist targets the correct stomach areas.
Traditional Chinese Medicine (TCM) is frequently used to manage gastric intestinal metaplasia in East Asia. Modern oncology centers often layer these formulas over conventional protocols. Specific compounds like Weifuchun and Elian aim to resolve chronic inflammation and encourage mucosal repair within the stomach lining.
Bookimed Expert Insight: A distinct pattern exists where patients at JCI-accredited Chinese hospitals, such as Fuda Cancer Hospital, receive highly specialized care featuring technologies like NanoKnife alongside traditional supportive treatments. While over 30,000 international patients have visited such facilities for late-stage support, the real value lies in combining TCM with high-precision radiotherapy guided by experts like Dr. Liu Shi Xin. This hybrid model prioritizes symptom control while maintaining strict endoscopic surveillance to monitor tissue changes objectively.
Patient Consensus: Patients note that herbal blends are often chosen for long-term care because they feel gentler than conventional drugs. Many emphasize that symptom relief shouldn't replace regular biopsies, as professional monitoring remains the only way to confirm disease reversal.
Protecting your stomach lining requires eliminating chemical irritants like NSAIDs and alcohol while adopting smaller meals to reduce mechanical pressure. Managing bacterial risks through hygiene helps prevent infections. These steps minimize inflammation and support the mucosal barrier. Consistency is vital for long-term gastric health and metaplasia management.
Bookimed Expert Insight: While dietary changes are essential, high-volume centers like Fuda Cancer Hospital emphasize diagnostic precision. They utilize technologies like narrow-band imaging during gastroscopy to monitor tissue changes. Patients should prioritize facilities that combine lifestyle coaching with advanced screening. This dual approach ensures that subtle shifts in the stomach lining are caught early. This is especially important when managed by specialists like Dr. Liu Shi Xin.
Patient Consensus: Patients note that switching to soft textures like congee and soups provides immediate relief during flares. They also emphasize tracking specific food triggers in a diary rather than following generic bans.